In recent years, targeted therapies, including those for fibroblast growth factor receptor 2 (FGFR2) fusions, isocitrate dehydrogenase 1 (IDH1) mutations, B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, and human epidermal growth factor receptor 2 (HER2) amplifications (Lamarca et al., 2022), along with immune checkpoint inhibitors (ICIs), are rapidly changing the treatment landscape for patients with advanced CCA (Mauro and Forner, 2023). The gene discussed is BRAF; the disease is cholangiocarcinoma.